On March 12, 2026 Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, reported highlights of PRP, its lead proenzyme therapy poised to potentially disrupt the $3 billion+ pancreatic cancer treatment market—one of oncology’s most desperate battlegrounds with a grim 13% five-year survival rate.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Conventional chemo hits walls of resistance, brutal toxicity, and minimal progress. PRP changes the game:
– >85% tumor growth inhibition demonstrated in preclinical pancreatic models
– Forces malignant cells to differentiate—attacking cancer at its root
– Reduces fibrosis and resistance markers in the tumor microenvironment
– Sensitizes resistant tumors to standard chemo—higher efficacy, lower toxicity
– Targets cancer stem cells to cut recurrence risk
"PRP may represent a true paradigm shift for pancreatic cancer patients," said Mr. James Nathanielsz, Propanc’s Chief Executive Officer. "We’re striking at the disease’s core mechanisms. With Phase 1b First-In-Human trials set for 2026 and a $100M facility in place, we’re moving fast to deliver real hope."
Propanc is advancing PRP toward clinical development for advanced solid tumors, with pancreatic and ovarian cancers as initial priorities.
(Press release, Propanc, MAR 12, 2026, View Source [SID1234663504])